FeesSafety
Pluang+

Interpace Biosciences Q3 revenue rises 18% to $10.4M with improved margins despite net loss

Company Fundamentals
16 Nov 2026, 23:01 WIB
GlobeNewsWire
View Source
Bullish
Interpace Biosciences Q3 revenue rises 18% to $10.4M with improved margins despite net loss

Interpace Biosciences reported Q3 2026 revenue of $10.4 million, an 18% increase year-over-year driven by a 7% rise in thyroid test volume and an 18% rise in thyroid revenue. Gross margin improved to 69%, and Adjusted EBITDA rose to $2.1 million, reflecting operational efficiency gains despite a net loss of $1.5 million due to non-recurring expenses. The company is focusing on its thyroid diagnostics business after discontinuing PancraGEN and is investing in automation and AI to support future growth. A pancreatic cancer testing program is in development but not expected to generate revenue until after 2027.

Interpace Biosciences' Q3 2026 results provide context for readers interested in health sector dynamics. For readers following health stocks, here is Pluang's market snapshot as of Nov 17, 2026 03:31 WIB: Among 150 priced US health-sector stocks, only 31 rose while 118 fell today. Arrowhead Pharmaceuticals (ARWR) dropped 6.28% to USD 44.78 with a typical hold time of 17 days, Sana Biotechnology (SANA) declined 6.19% to USD 1.90 despite 100% buy order activity and a longer hold time of 27 days, and Mesoblast Limited (MESO) fell 6.03% to USD 12.47 with an 18-day hold time. This contrasts with Interpace's reported growth in revenue and operational efficiency.

More News

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney's fiscal Q4 report, due November 17, is expected to show strong growth with analysts forecasting over 50% earnings per share (EPS) growth and more than 12% revenue increase. Streaming revenue rose 11% last quarter with margins hitting double d...

Company Fundamentals
Bullish
2 hours ago
Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox has launched a new Australia realm on Amazon Web Services (AWS) in the Sydney region, providing Australian government agencies and enterprises a local option for managing DNS, DHCP, and IP address management (DDI) with enhanced security. Thi...

Market News
Bullish
2 hours ago
European Commission approves RASONQUE for metastatic pancreatic cancer treatment

European Commission approves RASONQUE for metastatic pancreatic cancer treatment

The European Commission has approved RASONQUE (daraxonrasib), the first broad RAS-targeted oral medicine for adults with metastatic pancreatic adenocarcinoma who have had prior systemic therapy. This approval covers patients with or without identifie...

Market News
Bullish
3 hours ago
SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE, a European leader in multi-technical services, has acquired Dutch company Duflex B.V. to enhance its industrial automation, machine building, and robotics capabilities. Duflex, with 26 employees and €8 million revenue in 2025, specializes in ta...

Company Fundamentals
Bullish
4 hours ago
Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel Développement SAS disclosed that it repurchased a total of 3,878 of its own shares between November 9 and November 13, 2026. The average purchase price during this period was approximately €34.67 per share. This buyback is part of an authorized...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App